What clinical research has been conducted on BENLYSTA?
HGS released Phase II clinical trial results for BENLYSTA in June 2006. The results demonstrated that it significantly reduced disease activity versus a placebo in patients with clinically active lupus, and appeared generally safe and well-tolerated. In July 2009, HGS announced positive top-line results from the Phase III clinical trial, BLISS-52, which will continue to be analyzed. Results from the Phase III BLISS-76 clinical trial are expected to be released in November 2009. The design of the two trials is similar, but the duration of therapy in the two trials is different, 52 weeks for BLISS-52, and 76 weeks for BLISS-76.The BLISS-52 study was conducted primarily in Asia, South America, and Eastern Europe, and BLISS-76 is being conducted mostly in North America and Europe.
